Featured White Papers
- Oct. 14th: Simplified IT with Software-as-a-Service (SaaS) (ZDNet)
- The rise of Web commuting (Citrix Online)
- Choosing the best CRM for your organization (Oracle)
Content provided in partnership with
Technology Industry
Industry: Email Alert RSS FeedSmall Business Innovative Research
BT Catalyst, Dec, 1999
The National Institute of Diabetes and Digestive and Kidney Diseases has awarded a Phase I Small Business Innovative Research (SBIR) grant of $235,153 to Intronn LLC to research the use of its proprietary spliceosome mediated RNA trans-splicing technology to repair the gene defect underlying cystic fibrosis.
In the first phase of the project, the company intends to produce a series of pre-therapeutic RNA molecules that are capable of initiating spliceosome mediated RNA trans-splicing reactions with the mutant cystic fibrosis transmembrane regulator and repairing this mRNA in cultured cells from CF patients.
COPYRIGHT 1999 North Carolina Biotechnology Center
COPYRIGHT 2008 Gale, Cengage Learning
Find Research Guides for:
Find Featured Titles for: Business
- Academy of Marketing Science Review
- Accounting Historians Journal, The
- Accounting History
- AgExporter
- Agricultural Research
- Agricultural and Resource Economics Review
- Air Force Comptroller
- Air Safety Week
- Airline Industry Information
- American Demographics
- American Journal of Potato Research
- Architectural Review, The
- Asian Economic News
- Entrepreneur
Most Popular Articles in Technology
- An overview of continuous data protection
- Why all those current ratings?
- Many countries now have a mobile penetration rate above 100%, report says
- The Tata Group's big telecom gamble: VSNL's recent acquisition of Tyco ...
- MEASURING BANK BRANCH EFFICIENCY USING DATA ENVELOPMENT ANALYSIS: MANAGERIAL ...
- More »